Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation

Abstract The L/N-type calcium channel blocker cilnidipine has unique effects including sympathetic nerve suppression and the balanced vasodilatation of arteries and veins that may alleviate morning hypertension (MHT) or peripheral edema caused by calcium channel antagonists. We used ambulatory blood...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Society of Hypertension Vol. 5; no. 5; pp. 410 - 416
Main Authors Narita, Sumito, MD, Yoshioka, Yasuko, ST, Ide, Atsumi, RT, Kadokami, Toshiaki, MD, PhD, Momii, Hidetoshi, MD, PhD, Yoshida, Masayoshi, MD, Ando, Shin-ichi, MD, PhD
Format Journal Article
LanguageEnglish
Published United States 01.09.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract The L/N-type calcium channel blocker cilnidipine has unique effects including sympathetic nerve suppression and the balanced vasodilatation of arteries and veins that may alleviate morning hypertension (MHT) or peripheral edema caused by calcium channel antagonists. We used ambulatory blood pressure monitoring (ABPM) and a unique peripheral edema measurement to evaluate the effect of morning and bedtime cilnidipine in patients with MHT. Forty-three patients with MHT (60 ± 12 years) were randomly assigned to a morning or bedtime cilnidipine (10–20 mg/day). MHT was defined as a mean systolic blood pressure (SBP) ≥ 135 mm Hg by ABPM within 2 hours after awaking. After 3 months, greater SBP reductions were observed in the bedtime administration group (versus the morning administration group) at 3:30–6:00 AM (−24 ± 20 mm Hg vs. −10 ± 4 mm Hg; P < .05) and at 6:30–9:00 AM (−26 ± 15 mm Hg vs. −14 ± 17 mm Hg; P < .05). Although physical examinations showed leg edema in 16% of the patients, quantitative evaluations did not reveal significant volume gains. Cilnidipine had a greater effect on MHT, without causing significant leg edema, when administered at bedtime.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1933-1711
DOI:10.1016/j.jash.2011.03.008